TAXUS-IV Trial

Summary: Evaluated paclitaxel stents versus bare-metal stents. The primary endpoint of ischemia driven target vessel revascularization at 9 months was significantly reduced with paclitaxel stents.

Original Publication:

N Engl J Med. 2004 Jan 15;350(3):221-31.

Eponym: None